Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk.

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click here to find out why GDRX is a Buy.

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official website.